These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 34462871

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [Abstract] [Full Text] [Related]

  • 6. Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS/NRAS/BRAFV600 -Wild-Type Colorectal Cancer.
    Georgiou A, Stewart A, Cunningham D, Banerji U, Whittaker SR.
    Mol Cancer Res; 2020 Jun; 18(6):835-846. PubMed ID: 32098826
    [Abstract] [Full Text] [Related]

  • 7. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC, Tsai TY, Yadav VK, Deng L, Huang CC, Tzeng YM, Yeh CT, Chen MY.
    Int J Mol Sci; 2021 Jul 14; 22(14):. PubMed ID: 34299137
    [Abstract] [Full Text] [Related]

  • 8. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
    De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S.
    Lancet Oncol; 2010 Aug 14; 11(8):753-62. PubMed ID: 20619739
    [Abstract] [Full Text] [Related]

  • 9. Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial.
    Loree JM, Dowers A, Tu D, Jonker DJ, Edelstein DL, Quinn H, Holtrup F, Price T, Zalcberg JR, Moore MJ, Karapetis CS, O'Callaghan CJ, Waring P, Kennecke HF, Hamilton SR, Kopetz S.
    Clin Cancer Res; 2021 Jan 01; 27(1):52-59. PubMed ID: 33087330
    [Abstract] [Full Text] [Related]

  • 10. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):674-88. PubMed ID: 21398618
    [Abstract] [Full Text] [Related]

  • 11. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.
    Di Bartolomeo M, Pietrantonio F, Perrone F, Dotti KF, Lampis A, Bertan C, Beretta E, Rimassa L, Carbone C, Biondani P, Passalacqua R, Pilotti S, Bajetta E, Italian Trials in Medical Oncology Group.
    Target Oncol; 2014 Jun 20; 9(2):155-62. PubMed ID: 23821376
    [Abstract] [Full Text] [Related]

  • 12. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
    Ta TV, Nguyen QN, Chu HH, Truong VL, Vuong LD.
    Pathol Res Pract; 2020 Apr 20; 216(4):152898. PubMed ID: 32089414
    [Abstract] [Full Text] [Related]

  • 13. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
    Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F, CAPRI-GOIM investigators.
    Ann Oncol; 2015 Aug 20; 26(8):1710-4. PubMed ID: 25851630
    [Abstract] [Full Text] [Related]

  • 14. First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.
    Moiseyenko VM, Moiseyenko FV, Yanus GA, Kuligina ES, Sokolenko AP, Bizin IV, Kudriavtsev AA, Aleksakhina SN, Volkov NM, Chubenko VA, Kozyreva KS, Kramchaninov MM, Zhuravlev AS, Shelekhova KV, Pashkov DV, Ivantsov AO, Venina AR, Sokolova TN, Preobrazhenskaya EV, Mitiushkina NV, Togo AV, Iyevleva AG, Imyanitov EN.
    Clin Drug Investig; 2018 Jun 20; 38(6):553-562. PubMed ID: 29470838
    [Abstract] [Full Text] [Related]

  • 15. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.
    Oncogene; 2011 Feb 03; 30(5):561-74. PubMed ID: 20956938
    [Abstract] [Full Text] [Related]

  • 16. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
    Genet Med; 2013 Jul 03; 15(7):517-27. PubMed ID: 23429431
    [Abstract] [Full Text] [Related]

  • 17. Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study.
    Baba O, Bidikian A, Mukherji D, Shamseddin A, Temraz S, Fakhruddin N, Khazzouh M, Ghizzawi D, Abdel Khalek R, Zaatari G, Mahfouz R.
    Gene; 2022 Aug 05; 834():146646. PubMed ID: 35680020
    [Abstract] [Full Text] [Related]

  • 18. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
    Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S.
    Clin Cancer Res; 2013 Feb 01; 19(3):657-67. PubMed ID: 23251002
    [Abstract] [Full Text] [Related]

  • 19. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
    Liu YF, Feng ZQ, Chu TH, Yi B, Liu J, Yu H, Xue J, Wang YJ, Zhang CZ.
    Phytomedicine; 2024 Apr 01; 126():155462. PubMed ID: 38394734
    [Abstract] [Full Text] [Related]

  • 20. Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers.
    Kim SA, Park H, Kim KJ, Kim JW, Sung JH, Nam M, Lee JH, Jung EH, Suh KJ, Lee JY, Kim SH, Lee JO, Kim JW, Kim YJ, Kim JH, Bang SM, Lee JS, Lee KW.
    J Cancer Res Clin Oncol; 2022 Nov 01; 148(11):2995-3005. PubMed ID: 34853888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.